上海招聘

• Summary of the position:

Principle Scientist or Senior Scientist with expertise in in vitro pharmacology in oncology and immune-oncology, will provide scientific leadership and expertise to support multiple immuno-Oncology projects. The candidate must be competent to interact with cross-functional discovery project team. The person should actively strengthen the cancer immunotherapy pipeline through championing internal projects and managing/supporting collaborations with external partners.

Roles and Responsibilities：

• Design, execute and interpret studies on the development of biologic (bispecific antibodies) immunomodulators and immunomodulator combinations for the treatment of cancer using in vitro and ex vivo human immunology experimental systems.

• Work in collaboration with other team members in designing human immunology models to test new immumodulators also being tested in murine and other animal model systems.

• Analyzes complex issues significantly improves, changes or adapts existing methods and techniques.

• Develops research solutions that require extensive analysis and detailed investigation.

• Collaborate effectively with other colleagues across the global organization, as well as manage external collaborations with various industry partners.

• Present scientific results to multidisciplinary teams and senior management.

• Develops new ideas, concepts and approaches for immunotherapy and project workflow.

• Keeps on the look-out, develops, and incorporates when needed new assay technologies or platforms to expedite the research and improve data quality, reliability, and predictive value when moving to later stages of early clinical development.

Qualifications:

• PhD degree in a relevant scientific field (e.g. immunology, inflammation, cancer immunology, oncology), with a 2-3 years of post-PhD experience either in an industrial and/or academic setting is preferred

• A strong background in human cellular (tumor) immunology and immune regulation, preferably in the area of cancer immunotherapy, as evidenced by peer reviewed publications in top-tier journals, would be an important asset for this position.

• Experience with in vitro and ex vivo platform for evaluating the human immune tumor microenvironment, including but not limited to utilization of isolated primary human tumor/immune cell assays, CART cells, tumor explants, human PBMC assays.

• Hands-on experiences in development and deployment of functional assays using human cellular systems for drug discovery in highly desirable.

• Ability to conceptualize new ideas for immunotherapy and research assay tools.

• Familiarity with human and mouse tumor models and mechanisms of anti-tumor responses with strength in the analysis of the activity of human innate and adaptive cell populations and measuring anti-tumor effector lymphocyte responses.

• Excellent interpersonal skills with the ability to interact effectively with people, internally and externally.

• Team oriented work ethic and ability to work in cross-functional teams.

• Outstanding presentation and interpersonal communication skills.

• Ability to demonstrate effectiveness and growth in a fast-paced and dynamic team environment.

• PhD degree in a relevant scientific field (e.g. immunology, inflammation, cancer immunology, oncology), with a 2-3 years of post-PhD experience either in an industrial and/or academic setting is preferred.

• Working experience in related immuno-oncology field is preferred.
  

岸迈生物是一家创新型国际化生物技术企业，在上海和苏州分别设有研发中心和中试基地，专注于利用自主知识产权的双特异性抗体技术平台FIT-Ig进行创新生物药的研究和开发。FIT-Ig技术平台能够通过分子生物学手段将两个单抗序列糅合在一起形成一种结构独特的双特异性抗体，是全球***的既不需要任何氨基酸突变、也不包含连接肽链及任何非抗体序列的双特异性抗体技术，具备很高的成药性和产业化效率。基于FIT-Ig平台技术，岸迈生物正在针对肿瘤免疫和其他临床需求高的领域进行双特异性抗体系列原创产品的开发。岸迈生物同时也在通过全球范围内的技术授权、合作开发等多种形式实现平台的战略发展和产品多元化布局。
公司网页：**************
简历投递：hr@epimab.com
About EpimAb Biotherapeutic
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai？ with a proprietary unique and efficient technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties， without any mutations, peptide linkers, or non-Ig sequences. With this platform, EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit **************
Web:**************
Email:hr@epimab.com